Ø

3.

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

005914-0090-999 Total Pages Attorney Docket No. First Named Inventor or Application Identifier Michele Pagano

5 Express Mail Label No. EL 477 033 730 US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents. ADDRESS TO: Box Patent Application Washington, DC 20231 ☑ Fee Transmittal Form 7.

CD-ROM or CD-R in duplicate, large table or Computer (Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submissi Applicant claims Small Entity status, see 37 C.F.R. § 1.27 (if applicable, all necessary) ☑ Specification [Total Pages 109] ☑ Computer Readable Copy

(preferred arrangement set forth below) -Descriptive title of the Invention Paper Copy (identical to computer copy)

-Cross Reference to Related Applications -Statement Regarding Fed sponsored R&D c. Statement verifying identity of above copies -Reference to Microfiche Appendix -Background of the Invention ACCOMPANYING APPLICATION PARTS -Brief Summary of the Invention -Brief Description of the Drawings (if filed) 9. ☐ Assignment Papers (cover sheet & document(s)) -Detailed Description of the Invention (including drawings, if filed) -Claim(s) 10, D 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee) -Abstract of the Disclosure ☑ Drawing(s) (35 USC 113) [Total Sheets 80] English Translation Document (if applicable) 12. Information Disclosure Statement Copies of IDS ☑ Oath or Declaration [Total Sheets 2] (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14, Return Receipt Postcard (MPEP 503) b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 19 completed) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) i. DELETION OF INVENTORS(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) named in the prior 16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). application, see 37 CFR 1.63(d)(2) and 1.33 (b). Applicant must attach form PTO/SB/35 or it's equivalent ☐ Application Data Sheet. See 37 CFR 1.76 17. D Other: If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: □ Continuation □ Divisional □ Continuation-in-part (CIP) of prior application No: 19. CORRESPONDENCE ADDRESS Customer Number: 20583 (Insert Customer No. or Attach bar code label here) Joseph Marchaladada (Marchall or Correspondence address below

NAME **ADDRESS** CITY STATE ZIP CODE COUNTRY TELEPHONE FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Express Mail No.: EL 477 033 553 US

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW 1155 Avenue of Americas New York, N.Y. 10036-2711

ATTORNEY DOCKET NO. 9514-090-999

Date: January 7, 2002

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

The following Applicant(s): PAGANO, M.

Executed on: here with

Title of Invention: METHODS TO IDENTIFY COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE

AND DIFFERENTIATIVE DISORDERS

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE	
Total Claims	9	-20	0	\$18.00 each	\$	0.00
Independent	3	-3	0	\$84.00 each	\$	0.00
Minimum Fee					\$	740.00
Multiple Dependency Fee If Applicable (\$280.00)					\$	0.00
Total					\$	740.00
Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$	370.00
Total Filing Fee					\$	370.00

- DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- Priority of application no. 60/260,179 filed on January 5, 2001 in the United States Patent and Trademark Office is claimed under 35 U.S.C. § 119.
- The certified copy of the priority application has been filed in application no. filed
- Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is

enclosed.

Respectfully submitted,

1**3,77**-30,742

Laura A. Coruzzi
PENNIE & EDMONDS LLP

(Reg. No.)

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

NY2 - 1272850.1

EXPRESS MAIL NO.: EL 477 033 730 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: PAGANO, M.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: METHODS TO IDENTIFY COMPOUNDS Attorney Docket No.: 5914-090-999

USEFUL FOR THE TREATMENT OF

PROLIFERATIVE AND

DIFFERENTIATIVE DISORDERS

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Box SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer-readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090

Enclosure

Date: January 7, 2002

NY2 - 1273251.1